RecruitingPhase 2NCT06522594
REMAP ECMO - Beta Receptor Modulation Trial
Studying Cardiogenic shock
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Erasmus Medical Center
- Principal Investigator
- Christiaan L. MeuweseErasmus Medical Center
- Intervention
- Esmolol(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Study locations (1)
- Erasmus Medical Center, Rotterdam, South Holland, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06522594 on ClinicalTrials.govOther trials for Cardiogenic shock
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07527156Prolonged Nasogastric Administration of Ketones in Decompensated Heart FailureInstitute for Clinical and Experimental Medicine
- RECRUITINGNANCT07345559Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic ShockCMC Ambroise Paré
- RECRUITINGNANCT07374289On Scene ECPR in OstravaUniversity Hospital Ostrava
- RECRUITINGNCT07402018Intra-aortic Balloon Counterpulsation (IABC) ComplianceThomas Jefferson University
- RECRUITINGNCT07309029Pre-Emptive LAVA-ECMO for Complex High-Risk TAVRAtlantic Health System
- RECRUITINGNANCT07293923Magenta Elevate™ Clinical Feasibility Study in Cardiogenic ShockMagenta Medical Ltd.
- RECRUITINGNCT07354568Prognosis of Patients With Mixed Cardiogenic-Vasoplegic ShockCentre Hospitalier Universitaire, Amiens
- RECRUITINGNCT06964685Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic ShockAbiomed Inc.